Skip to main content
placeholder image

Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia

Journal Article


Abstract


  • Aims: To examine perceptions of extended-release (XR) buprenorphine injections among people who regularly use opioids in Australia. Design: Cross-sectional survey prior to implementation. XR-buprenorphine was registered in Australia in November 2018. Setting: Sydney, Melbourne and Hobart. Participants. A total of 402 people who regularly use opioids interviewed December 2017 to March 2018. Measurements: Primary outcome concerned the proportion of participants who believed XR-buprenorphine would be a good treatment option for them, preferred weekly versus monthly injections and perceived advantages/disadvantages of XR-buprenorphine. Independent variables concerned the demographic characteristics and features of current opioid agonist treatment (OAT; medication-type, dose, prescriber/dosing setting, unsupervised doses, out-of-pocket expenses and travel distance). Findings: Sixty-eight per cent [95% confidence interval (CI)��=��63���73%] believed XR-buprenorphine was a good treatment option for them. They were more likely to report being younger [26���35 versus >��55 years; odds ratio (OR)��=��3.16, 95% CI��=��1.12���8.89; P = 0.029], being female (OR��=��1.67, 95% CI��=��1.04���2.69; P = 0.034), <��10 years school education (OR��=��1.87, 95% CI��=��1.12���3.12; P = 0.016) and past-month heroin (OR��=��1.81, 95% CI��=��1.15���2.85; P��=��0.006) and methamphetamine use (OR��=��1.90, 95% CI��=��1.20���3.01; P��=��0.006). Fifty-four per cent reported no preference for weekly versus monthly injections, 7% preferred weekly and 39% preferred monthly. Among OAT recipients (n��=��255), believing XR-buprenorphine was a good treatment option was associated with shorter treatment episodes (1���2 versus �����2 years; OR��=��3.93, 95% CI��=��1.26���12.22; P��=��0.018), fewer unsupervised doses (�����8��doses past-month versus no take-aways; OR��=��0.50; 95% CI��=��0.27���0.93; P��=��0.028) and longer travel distance (�����5��versus <��5��km; OR��=��2.10, 95% CI��=��1.20���3.65; P��=��0.009). Sixty-nine per cent reported ���no problems or concerns��� with potential differences in availability, flexibility and location of XR-buprenorphine. Conclusions: Among regular opioid users in Australia, perceptions of extended-release buprenorphine as a good treatment option are associated with being female, recent illicit drug use and factors relating to the (in)convenience of current opioid agonist treatment.

Publication Date


  • 2020

Citation


  • Larance, B., Degenhardt, L., Grebely, J., Nielsen, S., Bruno, R., Dietze, P., . . . Farrell, M. (2020). Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia. Addiction, 115(7), 1295-1305. doi:10.1111/add.14941

Scopus Eid


  • 2-s2.0-85079064309

Start Page


  • 1295

End Page


  • 1305

Volume


  • 115

Issue


  • 7

Place Of Publication


Abstract


  • Aims: To examine perceptions of extended-release (XR) buprenorphine injections among people who regularly use opioids in Australia. Design: Cross-sectional survey prior to implementation. XR-buprenorphine was registered in Australia in November 2018. Setting: Sydney, Melbourne and Hobart. Participants. A total of 402 people who regularly use opioids interviewed December 2017 to March 2018. Measurements: Primary outcome concerned the proportion of participants who believed XR-buprenorphine would be a good treatment option for them, preferred weekly versus monthly injections and perceived advantages/disadvantages of XR-buprenorphine. Independent variables concerned the demographic characteristics and features of current opioid agonist treatment (OAT; medication-type, dose, prescriber/dosing setting, unsupervised doses, out-of-pocket expenses and travel distance). Findings: Sixty-eight per cent [95% confidence interval (CI)��=��63���73%] believed XR-buprenorphine was a good treatment option for them. They were more likely to report being younger [26���35 versus >��55 years; odds ratio (OR)��=��3.16, 95% CI��=��1.12���8.89; P = 0.029], being female (OR��=��1.67, 95% CI��=��1.04���2.69; P = 0.034), <��10 years school education (OR��=��1.87, 95% CI��=��1.12���3.12; P = 0.016) and past-month heroin (OR��=��1.81, 95% CI��=��1.15���2.85; P��=��0.006) and methamphetamine use (OR��=��1.90, 95% CI��=��1.20���3.01; P��=��0.006). Fifty-four per cent reported no preference for weekly versus monthly injections, 7% preferred weekly and 39% preferred monthly. Among OAT recipients (n��=��255), believing XR-buprenorphine was a good treatment option was associated with shorter treatment episodes (1���2 versus �����2 years; OR��=��3.93, 95% CI��=��1.26���12.22; P��=��0.018), fewer unsupervised doses (�����8��doses past-month versus no take-aways; OR��=��0.50; 95% CI��=��0.27���0.93; P��=��0.028) and longer travel distance (�����5��versus <��5��km; OR��=��2.10, 95% CI��=��1.20���3.65; P��=��0.009). Sixty-nine per cent reported ���no problems or concerns��� with potential differences in availability, flexibility and location of XR-buprenorphine. Conclusions: Among regular opioid users in Australia, perceptions of extended-release buprenorphine as a good treatment option are associated with being female, recent illicit drug use and factors relating to the (in)convenience of current opioid agonist treatment.

Publication Date


  • 2020

Citation


  • Larance, B., Degenhardt, L., Grebely, J., Nielsen, S., Bruno, R., Dietze, P., . . . Farrell, M. (2020). Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia. Addiction, 115(7), 1295-1305. doi:10.1111/add.14941

Scopus Eid


  • 2-s2.0-85079064309

Start Page


  • 1295

End Page


  • 1305

Volume


  • 115

Issue


  • 7

Place Of Publication